Can a black seed extract boost immunotherapy against a rare cancer?
NCT ID NCT05262556
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This pilot trial is testing whether adding NP-101, a compound from black seed oil, to two immunotherapy drugs (nivolumab and ipilimumab) can help control advanced or metastatic extra-pulmonary neuroendocrine carcinoma (EP-NECA) that has progressed after initial treatment. About 15 participants will receive the combination for up to six cycles. The main goal is to see if tumors shrink or stabilize, while also monitoring safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NP-101 (black seed oil extract) combined with nivolumab and ipilimumab
- What this could lead to
- If effective, this combination could offer a new second-line treatment option for people with advanced neuroendocrine carcinoma, potentially slowing tumor growth.
- What could go wrong
- This is a small early-phase pilot study, so results may not apply broadly. The combination may cause significant side effects, and the benefit over standard care is unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Two-Drug combo aims to stall rare gut tumors
- Could a PARP inhibitor boost chemo for tough lung cancer?
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial